메뉴 건너뛰기




Volumn 106, Issue 1, 2011, Pages 45-57

New oral anticoagulants in venous thromboembolism prophylaxis in orthopaedic patients: Are they really better?

Author keywords

Oral anticoagulants; Prophylaxis; Safety; Venous thromboembolism

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; APIXABAN; CARBAMAZEPINE; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; DABIGATRAN ETEXILATE; ENOXAPARIN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PHENOBARBITAL; PHENYTOIN; PLACEBO; POSACONAZOLE; RAZAXABAN; RIFAMPICIN; RITONAVIR; RIVAROXABAN; UNINDEXED DRUG; VORICONAZOLE; WARFARIN; XIMELAGATRAN;

EID: 79960050357     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-10-0653     Document Type: Review
Times cited : (12)

References (81)
  • 1
    • 46049090201 scopus 로고    scopus 로고
    • Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    • Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 381S-453S.
    • (2008) Chest , vol.133 , Issue.6 SUPPL.
    • Geerts, W.H.1    Bergqvist, D.2    Pineo, G.F.3
  • 2
    • 84855770091 scopus 로고    scopus 로고
    • QualityNet. Available at
    • QualityNet. SCIP project information. Available at: http://www.medqic.org/dcs/ ContentServer?cid=1122904930422&pagename=Medqic%2FContent%2FParentShellTemplate&parentName=Topic&c=MQParents. Accessed September 29, 2010.
    • (2010) SCIP project information , pp. 29
  • 3
    • 79960071278 scopus 로고    scopus 로고
    • Hospital Recognition Program
    • The Leapfrog Group., Available at
    • The Leapfrog Group. Hospital Recognition Program. Available at: http://www.leapfroggroup.org/for_hospitals/fh-incentives_and_rewards/hosp_rewards_prog. Accessed September 29, 2010.
    • (2010) Accessed September , pp. 29
  • 4
    • 60249096578 scopus 로고    scopus 로고
    • American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: What are the implications for clinicians and patients?
    • Eikelboom JW, Karthikeyan G, Fagel N, et al. American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? Chest 2009; 135: 513-520.
    • (2009) Chest , vol.135 , pp. 513-520
    • Eikelboom, J.W.1    Karthikeyan, G.2    Fagel, N.3
  • 5
    • 73249138865 scopus 로고    scopus 로고
    • Venous thromboembolism: Management by American Association of Hip and Knee Surgeons
    • Markel DC, York S, Liston MJ Jr, et al. Venous thromboembolism: management by American Association of Hip and Knee Surgeons. J Arthroplasty 2010; 25: 3-9.e2.
    • (2010) J Arthroplasty , vol.25
    • Markel, D.C.1    York, S.2    Liston Jr., M.J.3
  • 6
    • 45949103309 scopus 로고    scopus 로고
    • Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    • Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 160S-198S.
    • (2008) Chest , vol.133 , Issue.6 SUPPL.
    • Ansell, J.1    Hirsh, J.2    Hylek, E.3
  • 7
    • 33746020297 scopus 로고    scopus 로고
    • Ximelagatran: An eulogy
    • Boos CJ, Lip GY. Ximelagatran: an eulogy. Thromb Res 2006; 118: 301-304.
    • (2006) Thromb Res , vol.118 , pp. 301-304
    • Boos, C.J.1    Lip, G.Y.2
  • 8
    • 57849143295 scopus 로고    scopus 로고
    • Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran
    • Agnelli G, Eriksson BI, Cohen AT, et al. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res 2009; 123: 488-497.
    • (2009) Thromb Res , vol.123 , pp. 488-497
    • Agnelli, G.1    Eriksson, B.I.2    Cohen, A.T.3
  • 9
    • 0037048939 scopus 로고    scopus 로고
    • Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: The METHRO II randomised trial
    • Eriksson BI, Bergqvist D, Kälebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360: 1441-147.
    • (2002) Lancet , vol.360 , pp. 1441-1470
    • Eriksson, B.I.1    Bergqvist, D.2    Kälebo, P.3
  • 10
    • 0037329702 scopus 로고    scopus 로고
    • Direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement
    • Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003; 89: 288-296.
    • (2003) Thromb Haemost , vol.89 , pp. 288-296
    • Eriksson, B.I.1    Agnelli, G.2    Cohen, A.T.3
  • 11
    • 17444396697 scopus 로고    scopus 로고
    • Hepatic findings in long-term clinical trials of ximelagatran
    • Lee W, Larrey D, Olsson R, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Safety 2005; 28: 351-370.
    • (2005) Drug Safety , vol.28 , pp. 351-370
    • Lee, W.1    Larrey, D.2    Olsson, R.3
  • 12
    • 79960066577 scopus 로고    scopus 로고
    • Ximelagatran (Exanta): Alternative to warfarin?
    • Vaughan C. Ximelagatran (Exanta): alternative to warfarin? Proc (Bayl Univ Med Cent) 2005; 18: 76-80.
    • (2005) Proc (Bayl Univ Med Cent) , vol.18 , pp. 76-80
    • Vaughan, C.1
  • 13
    • 34147111008 scopus 로고    scopus 로고
    • Investigational treatments of venous thromboembolism
    • Spyropoulos AC. Investigational treatments of venous thromboembolism. Exp Opin Investig Drugs 2007; 16: 431-440.
    • (2007) Exp Opin Investig Drugs , vol.16 , pp. 431-440
    • Spyropoulos, A.C.1
  • 14
    • 11244325810 scopus 로고    scopus 로고
    • A phase II randomized, double-blind, five-arm parallel-group, dose-response study of a new oral directly-acting factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery
    • Abstract 41
    • Lassen MR, Davidson BL, Gallus A, et al. A phase II randomized, double-blind, five-arm parallel-group, dose-response study of a new oral directly-acting factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery. Blood 2003; 102: Abstract 41.
    • (2003) Blood , vol.102
    • Lassen, M.R.1    Davidson, B.L.2    Gallus, A.3
  • 15
    • 79960064061 scopus 로고    scopus 로고
    • ® (ximelagatran) tablets., 10 Accessed September Available at
    • ® (ximelagatran) tablets. FDA Advisory Committee Briefing Document. Cardiovascular and Renal Drugs Advisory Committee, 10 September 2004. Available at: www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4069B1_01_Astra Zeneca-Backgrounder.pdf. Accessed September 29, 2010.
    • (2004) FDA Advisory Committee Briefing Document. Cardiovascular and Renal Drugs Advisory Committee , vol.29 , Issue.2010
  • 16
    • 79960050693 scopus 로고    scopus 로고
    • Xarelto product monograph, Bayer Inc., Canada, September 10, Available at: Accessed September 29, 2010
    • Xarelto product monograph, Bayer Inc., Canada, September 10, 2008. Available at: www.bayer.ca/files/XARELTO-PM-ENG-10SEP2008-119111.pdf. Accessed September 29, 2010.
    • (2008)
  • 17
    • 79960040790 scopus 로고    scopus 로고
    • Xarelto® summary of product characteristics - EU, Bayer Schering Pharma AG, Germany, May, Available at
    • Xarelto® summary of product characteristics - EU, Bayer Schering Pharma AG, Germany, May 2009. Available at: http://www.xarelto.com/html/downloads/Xa relto_Summary_of_Product_Characteristics_May2009.pdf. Accessed September 29, 2010.
    • (2009) Accessed September , vol.29 , Issue.2010
  • 18
    • 79960062467 scopus 로고    scopus 로고
    • Pradax product monograph, Boehringer Ingelheim, Canada, July 31, Available at: Accessed September 29, 2010
    • Pradax product monograph, Boehringer Ingelheim, Canada, July 31, 2009. Available at: http://www.boehringer-ingelheim.ca/en/Home/Human_Health/ Our_Products/Product_Monographs/Pradax-pm.pdf. Accessed September 29, 2010.
    • (2009)
  • 19
    • 33748590510 scopus 로고    scopus 로고
    • Emerging anticoagulants for the treatment of venous thromboembolism
    • Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 2006; 96: 274-284.
    • (2006) Thromb Haemost , vol.96 , pp. 274-284
    • Weitz, J.I.1
  • 20
    • 34548456509 scopus 로고    scopus 로고
    • Beyond unfractionated heparin and warfarin: Current and future advances
    • Hirsh J, O'Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation 2007; 116: 552-560.
    • (2007) Circulation , vol.116 , pp. 552-560
    • Hirsh, J.1    O'Donnell, M.2    Eikelboom, J.W.3
  • 21
    • 13244266944 scopus 로고    scopus 로고
    • Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I
    • Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004; 2: 1573-1580.
    • (2004) J Thromb Haemost , vol.2 , pp. 1573-1580
    • Eriksson, B.I.1    Dahl, O.E.2    Ahnfelt, L.3
  • 22
    • 34548575058 scopus 로고    scopus 로고
    • Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial
    • Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956.
    • (2007) Lancet , vol.370 , pp. 949-956
    • Eriksson, B.I.1    Dahl, O.E.2    Rosencher, N.3
  • 23
    • 35449007749 scopus 로고    scopus 로고
    • Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial
    • Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-2185.
    • (2007) J Thromb Haemost , vol.5 , pp. 2178-2185
    • Eriksson, B.I.1    Dahl, O.E.2    Rosencher, N.3
  • 24
    • 57649123692 scopus 로고    scopus 로고
    • Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery
    • RE-MOBILIZE Writing Committee,
    • RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24: 1-9.
    • (2009) J Arthroplasty , vol.24 , pp. 1-9
    • Ginsberg, J.S.1    Davidson, B.L.2
  • 25
    • 60449115366 scopus 로고    scopus 로고
    • Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis
    • Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009; 101: 77-85.
    • (2009) Thromb Haemost , vol.101 , pp. 77-85
    • Wolowacz, S.E.1    Roskell, N.S.2    Plumb, J.M.3    Caprini, J.A.4    Eriksson, B.I.5
  • 26
    • 60849098445 scopus 로고    scopus 로고
    • Dabigatran etexilate for prevention of venous thromboembolism
    • Eikelboom JE, Weitz JI. Dabigatran etexilate for prevention of venous thromboembolism. Thromb Haemost 2009; 101: 2-4.
    • (2009) Thromb Haemost , vol.101 , pp. 2-4
    • Eikelboom, J.E.1    Weitz, J.I.2
  • 27
    • 33644867218 scopus 로고    scopus 로고
    • Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement
    • Eriksson BI, Borris L, Dahl OE, et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006; 4: 121-128.
    • (2006) J Thromb Haemost , vol.4 , pp. 121-128
    • Eriksson, B.I.1    Borris, L.2    Dahl, O.E.3
  • 28
    • 36348978071 scopus 로고    scopus 로고
    • The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement
    • Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5: 2368-2375.
    • (2007) J Thromb Haemost , vol.5 , pp. 2368-2375
    • Lassen, M.R.1    Davidson, B.L.2    Gallus, A.3
  • 29
    • 45949099359 scopus 로고    scopus 로고
    • Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
    • Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
    • (2008) N Engl J Med , vol.358 , pp. 2765-2775
    • Eriksson, B.I.1    Borris, L.C.2    Friedman, R.J.3
  • 30
    • 46049106502 scopus 로고    scopus 로고
    • Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial
    • Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-39.
    • (2008) Lancet , vol.372 , pp. 31-39
    • Kakkar, A.K.1    Brenner, B.2    Dahl, O.E.3
  • 31
    • 45949103416 scopus 로고    scopus 로고
    • Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthoplasty
    • Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthoplasty. N Engl J Med 2008; 358: 2776-2786.
    • (2008) N Engl J Med , vol.358 , pp. 2776-2786
    • Lassen, M.R.1    Ageno, W.2    Borris, L.C.3
  • 32
    • 65549169515 scopus 로고    scopus 로고
    • Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial
    • Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673-1680.
    • (2009) Lancet , vol.373 , pp. 1673-1680
    • Turpie, A.G.1    Lassen, M.R.2    Davidson, B.L.3
  • 33
    • 79960065619 scopus 로고    scopus 로고
    • U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Meeting of the Cardiovascular and Renal Drugs Advisory Committee March 19, Available at: Accessed September 29 2010
    • U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Meeting of the Cardiovascular and Renal Drugs Advisory Committee March 19, 2009. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM143660.pdf. Accessed September 29, 2010.
    • (2009)
  • 34
    • 68249158084 scopus 로고    scopus 로고
    • Apixaban or enoxaparin for thromboprophylaxis after knee replacement
    • Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361: 594-604.
    • (2009) N Engl J Med , vol.361 , pp. 594-604
    • Lassen, M.R.1    Raskob, G.E.2    Gallus, A.3
  • 35
    • 77649113258 scopus 로고    scopus 로고
    • ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomised double-blind trial
    • Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807-815.
    • (2010) Lancet , vol.375 , pp. 807-815
    • Lassen, M.R.1    Raskob, G.E.2    Gallus, A.3    Pineo, G.4    Chen, D.5    Hornick, P.6
  • 36
    • 78650587760 scopus 로고    scopus 로고
    • ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement
    • Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487-2498.
    • (2010) N Engl J Med , vol.363 , pp. 2487-2498
    • Lassen, M.R.1    Gallus, A.2    Raskob, G.E.3    Pineo, G.4    Chen, D.5    Ramirez, L.M.6
  • 37
    • 0037126649 scopus 로고    scopus 로고
    • Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States
    • Ostapowicz G, Fontana RJ, Schiødt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-954.
    • (2002) Ann Intern Med , vol.137 , pp. 947-954
    • Ostapowicz, G.1    Fontana, R.J.2    Schiødt, F.V.3
  • 38
    • 0041342015 scopus 로고    scopus 로고
    • Drug-induced hepatotoxicity
    • Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349: 474-485.
    • (2003) N Engl J Med , vol.349 , pp. 474-485
    • Lee, W.M.1
  • 39
    • 0028210921 scopus 로고
    • Use of enoxaparin, a low-molecular- weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group
    • Colwell CW Jr, Spiro TE, Trowbridge AA, et al. Use of enoxaparin, a low-molecular- weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 1994; 76: 3-14.
    • (1994) J Bone Joint Surg Am , vol.76 , pp. 3-14
    • Colwell Jr., C.W.1    Spiro, T.E.2    Trowbridge, A.A.3
  • 40
    • 0035168307 scopus 로고    scopus 로고
    • Elevation of hepatic transaminases after enoxaparin use: Case report and review of unfractionated and low-molecular-weight heparin- induced hepatotoxicity
    • Carlson MK, Gleason PP, Sen S. Elevation of hepatic transaminases after enoxaparin use: case report and review of unfractionated and low-molecular-weight heparin- induced hepatotoxicity. Pharmacotherapy 2001; 21: 108-113.
    • (2001) Pharmacotherapy , vol.21 , pp. 108-113
    • Carlson, M.K.1    Gleason, P.P.2    Sen, S.3
  • 41
    • 0026353206 scopus 로고
    • Biologic tolerance of two different low molecular weight heparins
    • Christiansen HM, Lassen MR, Borris LC, et al. Biologic tolerance of two different low molecular weight heparins. Semin Thromb Hemost 1991; 17: 450-454.
    • (1991) Semin Thromb Hemost , vol.17 , pp. 450-454
    • Christiansen, H.M.1    Lassen, M.R.2    Borris, L.C.3
  • 42
    • 34447338638 scopus 로고    scopus 로고
    • A replacement for warfarin: The search continues
    • Eikelboom JW, Weitz JI. A replacement for warfarin: the search continues. Circulation 2007; 116: 131-133.
    • (2007) Circulation , vol.116 , pp. 131-133
    • Eikelboom, J.W.1    Weitz, J.I.2
  • 43
    • 57449098437 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment
    • Stangier J, Stähle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 2008; 48: 1411-1419.
    • (2008) J Clin Pharmacol , vol.48 , pp. 1411-1419
    • Stangier, J.1    Stähle, H.2    Rathgen, K.3
  • 44
    • 34447317298 scopus 로고    scopus 로고
    • Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study
    • Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007; 116: 180-187.
    • (2007) Circulation , vol.116 , pp. 180-187
    • Agnelli, G.1    Gallus, A.2    Goldhaber, S.Z.3
  • 45
    • 47649098524 scopus 로고    scopus 로고
    • Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study
    • Botticelli Investigators Writing Committee
    • Botticelli Investigators Writing Committee, Buller H, Deitchman D, et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008; 6: 1313-1318.
    • (2008) J Thromb Haemost , vol.6 , pp. 1313-1318
    • Buller, H.1    Deitchman, D.2
  • 46
    • 67649563209 scopus 로고    scopus 로고
    • Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial
    • APPRAISE Steering Committee and Investigators
    • APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009; 119: 2877-2885.
    • (2009) Circulation , vol.119 , pp. 2877-2885
    • Alexander, J.H.1    Becker, R.C.2
  • 47
    • 33645231786 scopus 로고    scopus 로고
    • Review of the rebound phenomenon in new anticoagulant treatments
    • Hermans C, Claeys D. Review of the rebound phenomenon in new anticoagulant treatments. Curr Med Res Opin 2006; 22: 471-481.
    • (2006) Curr Med Res Opin , vol.22 , pp. 471-481
    • Hermans, C.1    Claeys, D.2
  • 48
    • 37549017626 scopus 로고    scopus 로고
    • Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation
    • Kubitza D, Mueck W, Becka M. Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation. Drug Saf 2008; 31: 67-77.
    • (2008) Drug Saf , vol.31 , pp. 67-77
    • Kubitza, D.1    Mueck, W.2    Becka, M.3
  • 49
    • 0031015345 scopus 로고    scopus 로고
    • Human P450 metabolism of warfarin
    • Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 67-74.
    • (1997) Pharmacol Ther , vol.73 , pp. 67-74
    • Kaminsky, L.S.1    Zhang, Z.Y.2
  • 50
    • 35148834736 scopus 로고    scopus 로고
    • Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) II. Clinical aspects
    • Aszalos A. Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) II. Clinical aspects. Drug Discov Today 2007; 12: 838-843.
    • (2007) Drug Discov Today , vol.12 , pp. 838-843
    • Aszalos, A.1
  • 51
    • 64349107688 scopus 로고    scopus 로고
    • Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
    • Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009; 157: 805-810.e1-2.
    • (2009) Am Heart J , vol.157
    • Ezekowitz, M.D.1    Connolly, S.2    Parekh, A.3
  • 52
    • 33750009690 scopus 로고    scopus 로고
    • The Petro-ex Investigators. Safety and efficacy of extended exposure to several doses of a new oral direct thrombin inhibitor dabigatran etexilate in atrial fibrillation [abstract].
    • The Petro-ex Investigators. Safety and efficacy of extended exposure to several doses of a new oral direct thrombin inhibitor dabigatran etexilate in atrial fibrillation [abstract]. Cerebrovasc Dis 2006; 21 (Suppl 4): 2.
    • (2006) Cerebrovasc Dis , vol.21 , Issue.SUPPL. 4 , pp. 2
  • 53
    • 35348879239 scopus 로고    scopus 로고
    • Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study)
    • Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007; 100: 1419-1426.
    • (2007) Am J Cardiol , vol.100 , pp. 1419-1426
    • Ezekowitz, M.D.1    Reilly, P.A.2    Nehmiz, G.3
  • 54
    • 70349306707 scopus 로고    scopus 로고
    • Dabigatran versus warfarin in patients with atrial fibrillation
    • Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
    • (2009) N Engl J Med , vol.361 , pp. 1139-1151
    • Connolly, S.J.1    Ezekowitz, M.D.2    Yusuf, S.3
  • 55
    • 79960062947 scopus 로고    scopus 로고
    • Preclinical pharmacokinetic and metabolism of apixaban, a potent and selective factor Xa inhibitor, Abstract 910
    • He K, He B, Grace JE, et al. Preclinical pharmacokinetic and metabolism of apixaban, a potent and selective factor Xa inhibitor. Blood 2006; 108: Abstract 910.
    • (2006) Blood , vol.108
    • He, K.1    He, B.2    Grace, J.E.3
  • 56
    • 66449099711 scopus 로고    scopus 로고
    • Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans
    • Weinz C, Schwarz T, Kubitza D, et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009; 37: 1056-1064.
    • (2009) Drug Metab Dispos , vol.37 , pp. 1056-1064
    • Weinz, C.1    Schwarz, T.2    Kubitza, D.3
  • 57
    • 17644400166 scopus 로고    scopus 로고
    • Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement
    • Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45: 555-563.
    • (2005) J Clin Pharmacol , vol.45 , pp. 555-563
    • Stangier, J.1    Eriksson, B.I.2    Dahl, O.E.3
  • 58
    • 33645779998 scopus 로고    scopus 로고
    • Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects
    • Kubitza D, Becka M, Zuehlsdorf M, et al. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006; 46: 549-558.
    • (2006) J Clin Pharmacol , vol.46 , pp. 549-558
    • Kubitza, D.1    Becka, M.2    Zuehlsdorf, M.3
  • 59
    • 0029818298 scopus 로고    scopus 로고
    • Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement
    • Bergqvist D, Benoni G, Björgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335: 696-700.
    • (1996) N Engl J Med , vol.335 , pp. 696-700
    • Bergqvist, D.1    Benoni, G.2    Björgell, O.3
  • 60
    • 0033539025 scopus 로고    scopus 로고
    • A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group
    • Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793-800.
    • (1999) N Engl J Med , vol.341 , pp. 793-800
    • Samama, M.M.1    Cohen, A.T.2    Darmon, J.Y.3
  • 61
    • 33750944556 scopus 로고    scopus 로고
    • Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients
    • McGarry LJ, Stokes ME, Thompson D. Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients. Thromb J 2006; 4: 17.
    • (2006) Thromb J , vol.4 , pp. 17
    • McGarry, L.J.1    Stokes, M.E.2    Thompson, D.3
  • 62
    • 79960051113 scopus 로고    scopus 로고
    • Available at
    • Lovenox product monograph, Sanofi-aventis, August 27, 2009. Available at: http://www.sanofi-aventis.ca/products/en/lovenox.pdf. Accessed September 29, 2010.
    • (2009) Lovenox product monograph Sanofi-Aventis A , vol.29 , Issue.2010
  • 63
    • 0033659872 scopus 로고    scopus 로고
    • Prevention of postoperative nausea and vomiting by continuous infusion of subhypnotic propofol in female patients receiving intravenous patient-controlled analgesia
    • Kim SI, Han TH, Kil HY, et al. Prevention of postoperative nausea and vomiting by continuous infusion of subhypnotic propofol in female patients receiving intravenous patient-controlled analgesia. Br J Anaesth 2000; 85: 898-900.
    • (2000) Br J Anaesth , vol.85 , pp. 898-900
    • Kim, S.I.1    Han, T.H.2    Kil, H.Y.3
  • 64
    • 65649094404 scopus 로고    scopus 로고
    • Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement
    • Eriksson BI, Kakkar AK, Turpie AG, et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br 2009; 91: 636-644.
    • (2009) J Bone Joint Surg Br , vol.91 , pp. 636-644
    • Eriksson, B.I.1    Kakkar, A.K.2    Turpie, A.G.3
  • 65
    • 4644293243 scopus 로고    scopus 로고
    • Hemorrhagic complications of anticoagulant treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    • Levine MN, Raskob G, Beyth RJ, et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): 287S-310S.
    • (2004) Chest , vol.126 , Issue.3 SUPPL.
    • Levine, M.N.1    Raskob, G.2    Beyth, R.J.3
  • 66
    • 31444446916 scopus 로고    scopus 로고
    • New anti-thrombotic agents: Emphasis on hemorrhagic complications and their management
    • Ng HJ, Crowther MA. New anti-thrombotic agents: emphasis on hemorrhagic complications and their management. Semin Hematol 2006; 43 (1 Suppl 1): S77-83.
    • (2006) Semin Hematol , vol.43 , Issue.1 SUPPL. 1
    • Ng, H.J.1    Crowther, M.A.2
  • 67
    • 79960062700 scopus 로고    scopus 로고
    • Practices in prevention of venous thromboembolism in primary hip and knee arthroplasty vary with surgeon operative volume: Findings from a survey of US orthopedic surgeons
    • Abstract PP-MO-248
    • Anderson FA, Lieberman J, Pellegrini VD, et al. Practices in prevention of venous thromboembolism in primary hip and knee arthroplasty vary with surgeon operative volume: findings from a survey of US orthopedic surgeons. J Thromb Haemost 2009; 7 (Suppl 2): Abstract PP-MO-248.
    • (2009) J Thromb Haemost , vol.7 , Issue.SUPPL. 2
    • Anderson, F.A.1    Lieberman, J.2    Pellegrini, V.D.3
  • 68
    • 0026761832 scopus 로고
    • Low molecular weight heparin in prevention of perioperative thrombosis
    • Leizorovicz A, Haugh MC, Chapuis FR, et al. Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 1992; 305: 913-920.
    • (1992) Br Med J , vol.305 , pp. 913-920
    • Leizorovicz, A.1    Haugh, M.C.2    Chapuis, F.R.3
  • 69
    • 0026718529 scopus 로고
    • Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis
    • Nurmohamed MT, Rosendaal FR, Büller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340: 152-156.
    • (1992) Lancet , vol.340 , pp. 152-156
    • Nurmohamed, M.T.1    Rosendaal, F.R.2    Büller, H.R.3
  • 70
    • 0028284442 scopus 로고
    • A meta-analysis of methods to prevent venous thromboembolism following total hip replacement
    • Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. J Am Med Assoc 1994; 271: 1780-1785.
    • (1994) J Am Med Assoc , vol.271 , pp. 1780-1785
    • Imperiale, T.F.1    Speroff, T.2
  • 71
    • 0033922465 scopus 로고    scopus 로고
    • A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty
    • Freedman KB, Brookenthal KR, Fitzgerald RH Jr, et al. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am 2000; 82-A: 929-938.
    • (2000) J Bone Joint Surg Am , vol.82 A , pp. 929-938
    • Freedman, K.B.1    Brookenthal, K.R.2    Fitzgerald Jr., R.H.3
  • 72
    • 33947575989 scopus 로고    scopus 로고
    • Failure of the American College of Chest Physicians-1A protocol for lovenox in clinical outcomes for thromboembolic prophylaxis
    • Burnett RS, Clohisy JC, Wright RW, et al. Failure of the American College of Chest Physicians-1A protocol for lovenox in clinical outcomes for thromboembolic prophylaxis. J Arthroplasty 2007; 22: 317-324.
    • (2007) J Arthroplasty , vol.22 , pp. 317-324
    • Burnett, R.S.1    Clohisy, J.C.2    Wright, R.W.3
  • 73
    • 0036159892 scopus 로고    scopus 로고
    • Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin
    • Crowther MA, Berry LR, Monagle PT, et al. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 2002; 116: 178-186.
    • (2002) Br J Haematol , vol.116 , pp. 178-186
    • Crowther, M.A.1    Berry, L.R.2    Monagle, P.T.3
  • 74
    • 69749100371 scopus 로고    scopus 로고
    • State-of-the-art review: Assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis
    • Hull RD, Yusen RD, Bergqvist D. State-of-the-art review: Assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis. Clin Appl Thromb Hemost 2009; 15: 377-388.
    • (2009) Clin Appl Thromb Hemost , vol.15 , pp. 377-388
    • Hull, R.D.1    Yusen, R.D.2    Bergqvist, D.3
  • 75
    • 17644409026 scopus 로고    scopus 로고
    • A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: The BISTRO II randomized trial
    • Eriksson BI, Dahl OE, Büller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3: 103-111.
    • (2005) J Thromb Haemost , vol.3 , pp. 103-111
    • Eriksson, B.I.1    Dahl, O.E.2    Büller, H.R.3
  • 76
    • 28444474155 scopus 로고    scopus 로고
    • BAY 59-7939: An oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study
    • Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005; 3: 2479-2486.
    • (2005) J Thromb Haemost , vol.3 , pp. 2479-2486
    • Turpie, A.G.1    Fisher, W.D.2    Bauer, K.A.3
  • 77
    • 33751559902 scopus 로고    scopus 로고
    • A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement
    • Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006; 114: 2374-2381.
    • (2006) Circulation , vol.114 , pp. 2374-2381
    • Eriksson, B.I.1    Borris, L.C.2    Dahl, O.E.3
  • 78
    • 34250651947 scopus 로고    scopus 로고
    • Dose-escalation study of rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor-for the prevention of venous thromboembolism in patients undergoing total hip replacement
    • Eriksson BI, Borris LC, Dahl OE, et al. Dose-escalation study of rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor-for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 2007; 120: 685-693.
    • (2007) Thromb Res , vol.120 , pp. 685-693
    • Eriksson, B.I.1    Borris, L.C.2    Dahl, O.E.3
  • 79
    • 64549107759 scopus 로고    scopus 로고
    • Concomitant administration of rivaroxaban - an oral, direct Factor Xa inhibitor - with clopidogrel and acetylsalicylic acid enhances antithrombosis in rats
    • Abstract P060
    • Perzborn E, Fischer E, Lange U. Concomitant administration of rivaroxaban - an oral, direct Factor Xa inhibitor - with clopidogrel and acetylsalicylic acid enhances antithrombosis in rats. Pathophysiol Haemost Thromb 2007/2008; 36 (Suppl 1): 157-200: Abstract P060.
    • (2007) Pathophysiol Haemost Thromb , vol.36 , Issue.SUPPL. 1 , pp. 157-200
    • Perzborn, E.1    Fischer, E.2    Lange, U.3
  • 80
    • 67649562905 scopus 로고    scopus 로고
    • Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, phase II trial
    • Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009; 374: 29-38.
    • (2009) Lancet , vol.374 , pp. 29-38
    • Mega, J.L.1    Braunwald, E.2    Mohanavelu, S.3
  • 81
    • 74249107395 scopus 로고    scopus 로고
    • The clinical implications of new oral anticoagulants: Will the potential advantages be achieved?
    • Phillips KW, Ansell J. The clinical implications of new oral anticoagulants: will the potential advantages be achieved? Thromb Haemost 2010; 103: 34-39.
    • (2010) Thromb Haemost , vol.103 , pp. 34-39
    • Phillips, K.W.1    Ansell, J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.